Laboratorios Farmaceutico... (LABFF)
Laboratorios Farmaceuticos Rovi S.A. Statistics
Share Statistics
Laboratorios Farmaceuticos Rovi S.A. has 51.15M shares outstanding. The number of shares has increased by -1.29% in one year.
| Shares Outstanding | 51.15M |
| Shares Change (YoY) | -1.29% |
| Shares Change (QoQ) | 0.91% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | n/a |
| FTD / Avg. Volume | n/a |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is 32.77 and the forward PE ratio is null. Laboratorios Farmaceuticos Rovi S.A.'s PEG ratio is -1.98.
| PE Ratio | 32.77 |
| Forward PE | n/a |
| PS Ratio | 5.87 |
| Forward PS | n/a |
| PB Ratio | 7.84 |
| P/FCF Ratio | 58.98 |
| PEG Ratio | -1.98 |
Enterprise Valuation
Laboratorios Farmaceuticos Rovi S.A. has an Enterprise Value (EV) of 4.57B.
| EV / Sales | 5.99 |
| EV / EBITDA | 22.02 |
| EV / EBIT | 33.07 |
| EV / FCF | 60.13 |
Financial Position
The company has a current ratio of 3.13, with a Debt / Equity ratio of 0.2.
| Current Ratio | 3.13 |
| Quick Ratio | 1.02 |
| Debt / Equity | 0.2 |
| Debt / EBITDA | 0.55 |
| Debt / FCF | 1.5 |
| Interest Coverage | 90.31 |
Financial Efficiency
Return on Equity is 23.93% and Return on Invested Capital is 19.78%.
| Return on Equity | 23.93% |
| Return on Assets | 16.45% |
| Return on Invested Capital | 19.78% |
| Revenue Per Employee | $347,632.68 |
| Profits Per Employee | $62,303.6 |
| Employee Count | 2,197 |
| Asset Turnover | 0.92 |
| Inventory Turnover | 0.86 |
Taxes
| Income Tax | 40.81M |
| Effective Tax Rate | 22.97% |
Stock Price Statistics
The stock price has increased by 5.3% in the last 52 weeks. The beta is 0.47, so Laboratorios Farmaceuticos Rovi S.A.'s price volatility has been higher than the market average.
| Beta | 0.47 |
| 52-Week Price Change | 5.3% |
| 50-Day Moving Average | 90.61 |
| 200-Day Moving Average | 89.51 |
| Relative Strength Index (RSI) | 52.01 |
| Average Volume (20 Days) | 25 |
Income Statement
In the last 12 months, Laboratorios Farmaceuticos Rovi S.A. had revenue of 763.75M and earned 136.88M in profits. Earnings per share was 2.67.
| Revenue | 763.75M |
| Gross Profit | 478.35M |
| Operating Income | 179.54M |
| Net Income | 136.88M |
| EBITDA | 207.69M |
| EBIT | 179.68M |
| Earnings Per Share (EPS) | 2.67 |
Balance Sheet
The company has 27.19M in cash and 114.41M in debt, giving a net cash position of -87.22M.
| Cash & Cash Equivalents | 27.19M |
| Total Debt | 114.41M |
| Net Cash | -87.22M |
| Retained Earnings | 486.21M |
| Total Assets | 832.02M |
| Working Capital | 332.95M |
Cash Flow
In the last 12 months, operating cash flow was 138.28M and capital expenditures -62.22M, giving a free cash flow of 76.06M.
| Operating Cash Flow | 138.28M |
| Capital Expenditures | -62.22M |
| Free Cash Flow | 76.06M |
| FCF Per Share | 1.48 |
Margins
Gross margin is 62.63%, with operating and profit margins of 23.51% and 17.92%.
| Gross Margin | 62.63% |
| Operating Margin | 23.51% |
| Pretax Margin | 23.27% |
| Profit Margin | 17.92% |
| EBITDA Margin | 27.19% |
| EBIT Margin | 23.51% |
| FCF Margin | 9.96% |
Dividends & Yields
LABFF pays an annual dividend of $1.1, which amounts to a dividend yield of 1.22%.
| Dividend Per Share | $1.10 |
| Dividend Yield | 1.22% |
| Dividend Growth (YoY) | -14.69% |
| Payout Ratio | 35.26% |
| Earnings Yield | 3.05% |
| FCF Yield | 1.7% |
Analyst Forecast
Currently there are no analyst rating for LABFF.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 14.7 |
| Piotroski F-Score | 7 |